SOUTH SAN FRANCISCO, Calif., June 18 /PRNewswire-FirstCall/-- Exelixis, Inc. announced today that Michael Morrissey, president of research and development of Exelixis will present at the Second Annual Piper Jaffray London Health Care Conference at 10:00 a.m. (BST) / 2:00 a.m. (PT) on Thursday, June 21, 2007.
The presentation will be webcast and may be accessed in the Event Calendar page under Investors on the Exelixis website at http://www.exelixis.com.
About Exelixis
Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis’ broad product pipeline includes investigational compounds in Phase II and Phase I clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company’s web site at http://www.exelixis.com.
Exelixis, Inc.
CONTACT: Charles Butler, Director, Investor Relations, +1-650-837-7277,cbutler@exelixis.com, or Soleil Maxwell Harrison, Senior Manager, CorporateCommunications, +1-650-837-7012, sharrison@exelixis.com, both of Exelixis,Inc.
Web site: http://www.exelixis.com/
